No. |
Title |
Author |
Journal |
Vol&Page |
Year |
Pub Med ID |
原文 |
Immuno-cell therapy of cancer in Japan. |
Egawa K |
Anticancer Res. |
24(5C):3321-6. |
2004 |
|
1 |
A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. |
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Vetto JT, Seipp CA, Simpson C. |
Surgery. |
100(2):262-72. |
1986 |
|
5 |
The effect of localized therapy with postsurgical local recurrence of lung carcinoma and metastatic lung tumors. |
Baba M, Yamaguchi Y, Fujisawa T, et al. |
Jpn J Cancer Chemother |
15: 1342-1350 |
1988 |
|
6 |
Transcatheter arterial injection of autologous lymphokine-activated killer (LAK) cells into patients with liver cancers. |
Komatsu T, Yamauchi K, Furukawa T, Obata H. |
J Clin Immunol. |
10(3):167-74. |
1990 |
|
7 |
Study on adoptive immunotherapy in patients with renal cell carcinoma. II. Plasmapheresis with adoptive immunotherapy using LAK cells and IL-2 |
Usui A. |
Nippon Hinyokika Gakkai Zasshi. |
81(7):1058-64. |
1990 |
|
8 |
LAK cell adoptive immunotherapy and its problems |
Yamaguchi Y, Takayama T, Kawami H, Sato Y, Baba N, Kuroi K, Toge T. |
Nippon Geka Gakkai Zasshi. |
92(9):1234-6. |
1991 |
|
9 |
Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2 |
Nakano E, Iwasaki A, Seguchi T, Sugao H, Tada Y, Matsuda M, Sonoda T. |
Nippon Hinyokika Gakkai Zasshi. |
82(3):395-404. |
1991 |
|
10 |
Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. |
Aoki Y, Takakuwa K, Kodama S, Tanaka K, Takahashi M, Tokunaga A, Takahashi T |
Cancer Res. |
51(7):1934-9. |
1991 |
|
11 |
Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation |
Nomura K, Fujioka T. |
Nippon Hinyokika Gakkai Zasshi. |
84(5):831-40 |
1993 |
|
12 |
Effect of local administration of lymphokine-activated killer cells and interleukin-2 on malignant brain tumor patients. |
Ibayashi Y, Yamaki T, Kawahara T, Daibo M, Kubota T, Uede T, Tanabe S, Hashi K. |
Neurol Med Chir (Tokyo). |
33(7):448-57. |
1993 |
|
13 |
Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK cell and CTL therapy.
|
Haruta I, Yamauchi K, Aruga A, Komatsu T, Takasaki K, Hayashi N, Hanyu F. |
J Immunother Emphasis Tumor Immunol. |
19(3):218-23. |
1996 |
|
14 |
Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results. |
Tomita Y, Katagiri A, Saito K, Imai T, Saito T, Tanikawa T, Terunuma M, Nishiyama T, Takahashi K. |
Int J Urol. |
5(1):16-21. |
1998 |
|
15 |
Locoregional cellular immunotherapy for patients with advanced esophageal cancer. |
Toh U, Yamana H, Sueyoshi S, Tanaka T, Niiya F, Katagiri K, Fujita H, Shirozou K, Itoh K. |
Clin Cancer Res. |
6(12):4663-73. |
2000 |
|
16 |
Clinical benefit of non-toxic therapy in patients with advanced cancer (opinion).
|
Goto S, Shirotani N, Hatakeyama M, Tagami C, Arakawa H, Kuwata E, Noguchi K, Egawa K |
Anticancer Res. |
22(4):2461-4. |
2002 |
|
17 |
Life-prolonging effect of immunocell BAK (BRM-activated killer) therapy for advanced solid cancer patients: prognostic significance of serum immunosuppressive acidic protein levels. |
Ebina T, Ogama N, Shimanuki H, Kubota T, Isono N. |
Cancer Immunol Immunother. |
52(9):555-60 |
2003 |
|
18 |
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. |
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al. |
N Engl J Med. |
316(15):889-97. |
1987 |
|
19 |
Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. |
Steis RG, Urba WJ, VanderMolen LA, Bookman MA, Smith JW 2nd, Clark JW, Miller RL, Crum ED, Beckner SK, McKnight JE, et al. |
J Clin Oncol. |
8(10):1618-29. |
1990 |
|
20 |
Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. |
Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, Bush WH Jr, Benz LA, Fefer A. |
J Clin Oncol. |
10(6):960-8. |
1992 |
|
21 |
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. |
Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, et al. |
J Natl Cancer Inst. |
85(8):622-32. |
1993 |
|
22 |
Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies. |
Kimoto Y, Tanaka T, Tanji Y, Fujiwara A, Taguchi T. |
Biotherapy. |
8(1):41-50. |
1994 |
|
23 |
Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. |
Fujita K, Ikarashi H, Takakuwa K, Kodama S, Tokunaga A, Takahashi T, Tanaka K. |
Clin Cancer Res. |
1(5):501-7. |
1995 |
|
24 |
A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. |
Kimura H, Yamaguchi Y. |
Cancer. |
80(1):42-9. |
1997 |
|
25 |
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. |
Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. |
Lancet. |
356(9232):802-7. |
2000 |
|
26 |
Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. |
Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, Sekikawa T, Matsumoto Y. |
Clin Cancer Res. |
8(6):1767-71. |
2002 |
|
